BloodLine Presents: Updates on Current Treatment Options for Cytomegalovirus (CMV) in the Transplant Setting
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.
Webcast: Breakthrough Therapies for Acute Graft-Versus-Host-Disease
Click the “Start Activity” button to indicate you have reviewed the CME information for this activity. Activity Speakers James Ferrara, MD, DSc Program Chair Ward-Coleman Chair in Cancer Medicine Professor and Director Hematologic Malignancies...Blood and Marrow Transplantation Reviews – Optimal Use of Stem Cell Mobilization in Patients with Hematologic Malignancies
Hodgkin lymphoma (HL) is a pathologically and clinically heterogeneous hematologic malignancy. In the United States, an estimated 185,000 people are currently living with this disease, and it accounted for more than 9,000 new cases of cancer in 2015. Chemotherapy and radiation provide long-term benefit to the majority of patients with HL; however, some patients will eventually relapse.